When talking about COVID-19 treatment, the set of medical approaches used to manage infection by SARS‑CoV‑2. Also known as coronavirus therapy, it spans drugs, preventive shots, and bedside care.
One core pillar is antiviral drugs, medications that directly block viral replication. These include oral agents like nirmatrelvir‑ritonavir and intravenous remdesivir. A second pillar is vaccines, preventive biologics that prime the immune system against the virus. Even after vaccination, breakthrough cases often need added tools such as monoclonal antibodies, lab‑engineered proteins that neutralize the virus. Together they form a layered defense that reduces hospitalizations and death.
Effective COVID-19 treatment follows a simple logic: early detection, targeted therapy, and supportive care. Rapid testing lets clinicians start antivirals within the first five days, when they’re most potent. If the disease progresses, supportive care—oxygen, fluid management, and anti‑inflammatory steroids—keeps organs functioning while the immune system clears the infection. Clinical trials continue to refine dosing, combo regimens, and new targets, so staying updated matters.
Beyond drugs, several related concepts shape how treatment works. Symptom management includes over‑the‑counter pain relievers, cough suppressants, and breathing exercises that improve comfort. Risk stratification identifies patients with obesity, diabetes, or heart disease who may need aggressive therapy earlier. Post‑COVID care addresses lingering fatigue, lung scarring, or neurological issues that emerge weeks after the acute phase.
The articles below dive deeper into each of these areas: comparisons of antiviral options, updates on vaccine efficacy against new variants, practical guides for using monoclonal antibodies, and tips for managing long‑term symptoms. Whether you’re a patient looking for clear next steps or a professional needing the latest evidence, the collection offers concise, actionable information to help you navigate COVID‑19 treatment today.
Oct
A detailed, human‑written comparison of Molnupiravir with Paxlovid, Remdesivir, and monoclonal antibodies, covering efficacy, safety, usage scenarios, and FAQs.
Jul 16 2025
Mar 25 2025
Jun 26 2025
Sep 24 2025
Mar 20 2025